Thelansis

Cardiac Amyloidosis Market Outlook Thelansis’s “Cardiac Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cardiac Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What...

  Cardiac Amyloidosis Market Outlook Thelansis’s “Cardiac Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cardiac Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Cardiac Amyloidosis Overview Cardiac amyloidosis is a serious and often underdiagnosed infiltrative heart condition caused by the extracellular deposition of abnormal, misfolded proteins (amyloid fibrils) within the heart muscle and surrounding tissues. These insoluble protein deposits lead to progressive thickening and stiffening of the heart walls, impairing its ability to pump blood effectively and disrupting its electrical system, ultimately...

  Systemic amyloidosis encompasses a group of diseases characterized by the deposition of misfolded fibrillar proteins in the extracellular matrix. Over 30 different precursor proteins can undergo substantial molecular transformations to form amyloid fibrils in vivo. Two primary types of amyloid commonly infiltrate the cardiac tissue: immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. In systemic amyloidosis, cardiac involvement is the primary cause of morbidity and mortality, irrespective of the specific mechanism underlying amyloid production. Both light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) can affect the heart, leading to symptoms such as heart failure, arrhythmias, and other extracardiac manifestations. AL amyloidosis is relatively rare, while ATTR has varying clinical penetrance and is associated with different variants. The pathophysiology involves the extracellular deposition of misfolded protein amyloid fibrils, compro...